CD274 and cancer: While the blockade of the inhibitory checkpoint PD-1/PD-L1 has become a well-established treatment strategy for several cancer entities, including recurrent/metastatic HNSCC, relevant relapse rates post-treatment require the exploration of additional immune checkpoints and cytokines involved in stimulating TILs (43, 49, 50).